Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.tps526
Abstract: TPS526Background: Heat shock protein 90 (HSP90) has a central role in modulating tumor microenvironment, inflammatory signaling pathways (NF-κB, HIF-1α and Jak-STAT), tumor antigen presentation and... read more here.
Keywords: advanced gastrointestinal; xl888 patients; pembrolizumab xl888; patients advanced ... See more keywords